muscle stem cells fused into multinucleated myotubes

Innovation & Licensing

Our technology offers

The Max Delbrück Center has a unique record of discovery and innovation leading to a diverse technology portfolio.

To find solutions for your business and technology needs, have a look at our technology offers on the website of our commercialization partner Ascenion. 

We also encourage you to contact us for more information about current technology development at the Max Delbrück Center and the researchers behind them.

Intellectual property & patents

The Max Delbrück Center holds patents for technologies in 86 areas (including products and applications), with a total of 571 successful patents worldwide.

About the header image
mRNA introduced the gene editor CRISPR-Cas9 into human muscle stem cells

The researchers used mRNA to introduce the gene editor CRISPR-Cas9 into human muscle stem cells. These cells fused into multinucleated myotubes following mRNA-mediated CRISPR-Cas9 gene editing. A myosin heavy chain is seen in green and the nuclei in blue.

Further information